This therapeutic direction gained more support after the argatroban with recombinant tissue plasminogen activator for acute stroke-2 trial,[21] which proved that stroke patients treated with rtPA and adjunctive argatroban—a direct thrombin inhibitor—had no increased risk of SICH. The gene discussed is PLAT; the disease is stroke disorder.